Key result
Sodium orthovanadate counteracted the upregulation of PTEN induced by long-term atorvastatin treatment, protecting cardiac cells against ischemia/reperfusion injury via Akt signaling.
Why the study?
Does sodium orthovanadate improve protection against ischemia/reperfusion injury in an in vitro rat myocardial model treated with chronic atorvastatin?
Does sodium orthovanadate improve protection against ischemia/reperfusion injury in an in vitro rat myocardial model treated with chronic atorvastatin?
Inhibition of PTEN by sodium orthovanadate counteracts the PTEN upregulation caused by chronic atorvastatin, thereby preserving Akt-mediated protection against myocardial ischemia/reperfusion injury.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat models for countering atorvastatin-induced PTEN effects; leaves open clinical relevance for ischemia/reperfusion protection.
Acute statin treatment has been reported to be critical in protecting the cardiac cells against ischemia/reperfusion injury by activating PI3K/Akt signal pathway. In vitro rat myocardial ischemia/reperfusion model, chronic statin treatment led to upregulation of phosphatase and tensin homolog (PTEN). This has been potentially indicated the correlation in PTEN and protective effect of statin on myocardium. In this current study, we evaluated the role of sodium orthovanadate a nonspecific inhibitor to PTEN and its correlation with atorvastatin on protecting myocardium against ischemia/reperfusion injury. We found a long-term statin treatment could increase the PTEN level, and this process was counteracted in the presence of sodium orthovanadate. However, the phosphotyrosine level was not affected by this statin. Besides, this process was mediated by Akt signaling since phosphorylated Akt level was altered by statin and sodium orthovanadate treatment. In a conclusion, this study showed a potential mechanism underlying PTEN-induced attenuation in long-term statin's therapeutic effect, which provided the new insight into the synergic role of PTEN and atorvastatin in protecting cardiac cells against ischemia/reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2018) studied Myocardial ischemia/reperfusion injury. Sodium orthovanadate and chronic atorvastatin was evaluated on PTEN level and phosphorylated Akt level. Sodium orthovanadate counteracted the upregulation of PTEN induced by long-term atorvastatin treatment, protecting cardiac cells against ischemia/reperfusion injury via Akt signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: